IGF-1 LR3 vs Leuphasyl
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Leuphasyl
Leuphasyl (Pentapeptide-18) is a cosmetic peptide that reduces muscle tension through a mechanism similar to enkephalins. Often combined with Syn-Ake for enhanced anti-wrinkle effects.
Full details →Side-by-Side Comparison
| Aspect | IGF-1 LR3 | Leuphasyl |
|---|---|---|
| Mechanism | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Mimics enkephalin and binds to enkephalin receptors on muscle cells, reducing acetylcholine release and thereby decreasing muscle contraction intensity. |
| Typical Dosage | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | Topical: 3-8% concentration in serums. Often used in combination products with other muscle-relaxing peptides. |
| Administration | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | Topical application to expression lines. Best results with consistent twice-daily use over 8+ weeks. |
| Side Effects | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Very well-tolerated topically. No significant adverse effects reported at cosmetic concentrations. |
| Best For |